ArticleJournal of applied toxicology : JAT2026
Safety Assessment and Hypoglycemic Effect of Moringa oleifera Lam. Seed Lectin (WSMoL) in Alloxan-Induced Diabetic Mice.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Moringa oleifera Lam. seeds contain WSMoL, a lectin previously studied for toxicity and pharmacological effects. In this study, we investigated WSMoL (10, 25, or 50 mg/kg i.p.) for acute and 14-day repeated-dose toxicity, as well as genotoxicity, in Swiss mice. In addition, the hypoglycemic activity of WSMoL (25 and 50 mg/kg i.p.) was evaluated in alloxan-treated mice. Animals were monitored for body weight, water and food consumption, behavioral changes, hematological and biochemical parameters, and histological patterns of the liver, spleen, and kidneys. Acute toxicity assay showed that WSMoL did not cause mortality or changes in behavior, food and water intake, or body weight. However, its administration resulted in monocytopenia, and histological changes consistent with an inflammatory process. The repeated-dose assay also indicated no significant alterations in body weight, water, or food intake. Hematological analyses, however, revealed monocytopenia and lymphocytopenia, and histological changes consistent with inflammation were observed. The micronucleus test in bone marrow cells indicated that WSMoL was not genotoxic. Administration of WSMoL (25 and 50 mg/kg) significantly reduced fasting blood glucose levels and improved oral glucose tolerance in both male and female animals after 10 days of treatment. Interestingly, WSMoL at 50 mg/kg reduced blood glucose to levels comparable to insulin. Histological analyses suggest that WSMoL prevented liver and kidney damage induced by hyperglycemia. Overall, our results indicate that WSMoL is a promising natural alternative for diabetes treatment, but its use should be approached with caution due to potential subclinical toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.